Dark

Check out our API

CLXPF
Cybin, Inc. Common Shares
stock OTC

Inactive

Aug 4, 2021

3.02USD-1.307%(-0.04)864,336

Pre-market

0.00USD-100.000%(-3.06)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Aug 23, 2021

10:43AM EDT Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy Benzinga

Aug 11, 2021

02:56PM EDT What Do You Really Know About Psychedelics And Psychedelics Stocks? Benzinga

Aug 9, 2021

08:26PM EDT Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies Benzinga

Aug 6, 2021

11:57AM EDT These OTC Securities Had the Most Trading Activity in July Benzinga

Aug 5, 2021

02:51PM EDT Cybin Becomes First Psychedelics Company On The NYSE: CEO Explains Everything You Need To Know Benzinga

Aug 4, 2021

07:00AM EDT Cybin to Commence Trading on the NYSE American on August 5 Business Wire

Aug 3, 2021

02:25PM EDT Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies Benzinga

Aug 2, 2021

10:08AM EDT Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected Benzinga

Jul 28, 2021

07:43PM EDT Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5 Business Wire

Jul 26, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021 Benzinga

09:36AM EDT HC Wainwright & Co. Initiates Coverage On Cybin with Buy Rating, Announces Price Target of $8 Benzinga

08:02AM EDT Psyched: Cybin And Field Trip Head To Wall Street, AOC Pushes For Federal Psychedelics Research, Off-Label Ketamine Covered By Insurance In Canada Benzinga

Jul 23, 2021

06:10PM EDT Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To 'Psychedelics Renaissance' Benzinga

05:04PM EDT Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance" Benzinga

Jul 22, 2021

02:03PM EDT Cybin Lands Conditional Approval To Become The First Psychedelics Company on The NYSE Benzinga

Jul 21, 2021

08:37PM EDT Cybin Announces Conditional Listing Approval from NYSE American Business Wire

Jul 20, 2021

09:16AM EDT These OTC Securities Had the Most Trading Activity in June Benzinga

Jul 13, 2021

07:03AM EDT Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy Business Wire

Jul 12, 2021

08:42AM EDT Psyched: Numinus, MindMed, Cybin Reach Milestones, Harvard To Study Psychedelics Law, Michael Pollan Dives Into Mescaline Benzinga

Jul 9, 2021

07:00AM EDT Cybin to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th Business Wire

Jul 8, 2021

06:00PM EDT Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio Business Wire

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021 Benzinga

09:33AM EDT Aegis Capital Initiates Coverage On Cybin with Buy Rating, Announces Price Target of $9 Benzinga

Jul 7, 2021

01:51PM EDT Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies Benzinga

Jul 6, 2021

07:00AM EDT Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of Excellence Business Wire

Jul 3, 2021

12:32PM EDT Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies Benzinga

Jun 30, 2021

06:14PM EDT Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More Benzinga

Jun 28, 2021

10:41PM EDT Cybin Inc Biotech Co Reports $51 Million In Cash As Stifel Ups Price Target To $12 Benzinga

08:35AM EDT Life Sciences Investor Forum today announced that the presentations from the June 24th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. GlobeNewswire Inc

08:06AM EDT Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement Business Wire

08:03AM EDT Cybin Inc. Releases Annual Financials and Provides Business Highlights Business Wire

Jun 25, 2021

07:00AM EDT Cybin to Participate in Grizzle Psychedelics Con on June 28th Business Wire

Jun 24, 2021

07:00AM EDT Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board Business Wire

Jun 23, 2021

08:35AM EDT Cybin Inc.(NEO:CYBN) (OTCQB:CLXPF) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Life Sciences Investor Forum on June 24, 2021. The presentation details are as follows: GlobeNewswire Inc

Jun 22, 2021

07:00AM EDT Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study Business Wire

Jun 21, 2021

10:22AM EDT Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform Benzinga

08:35AM EDT Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. GlobeNewswire Inc

07:00AM EDT EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 10th Emerging Growth Conference. GlobeNewswire Inc

Jun 18, 2021

04:22PM EDT Cybin to Present at the Emerging Growth Conference on June 23rd Business Wire

Jun 16, 2021

07:00AM EDT Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004 Business Wire

Jun 14, 2021

09:18AM EDT Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers Benzinga

Jun 11, 2021

04:15PM EDT Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th Business Wire

Jun 8, 2021

05:15PM EDT Cybin To Co-Sponsor Clinical Trial Testing Psilocybin In Frontline Health Workers With Covid-related Distress Benzinga

01:12PM EDT What Do You Really Know About Psychedelics And Psychedelics Stocks? Benzinga

07:10AM EDT Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy Benzinga

Jun 7, 2021

06:51AM EDT Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York Benzinga

Jun 2, 2021

05:59PM EDT Cybin to Present at the 2021 LD Micro Invitational XI on June 10, 2021 Business Wire

Jun 1, 2021

07:00AM EDT Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine's Psychedelic Effects on Cerebral Cortex Hemodynamics Business Wire

May 28, 2021

07:00AM EDT Cybin to Present at the Jefferies Virtual Healthcare Conference 2021 Business Wire

May 27, 2021

09:18AM EDT Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week Benzinga

May 26, 2021

07:00AM EDT Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions Business Wire

May 24, 2021

08:33AM EDT Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research Benzinga

May 20, 2021

07:00AM EDT Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms Business Wire

May 19, 2021

10:27AM EDT Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week Benzinga

May 18, 2021

07:00AM EDT Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder Business Wire

May 11, 2021

10:40AM EDT Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week Benzinga

May 6, 2021

04:30PM EDT Cybin to Present at the Benzinga Global Small Cap Conference Business Wire

May 4, 2021

09:24AM EDT Psyched: MindMed's Nasdaq Debut, PharmaDrug Gets Orphan Drug Designation For DMT, Numinus Launches Clinical Trial Of Naturally Derived Psilocybin Benzinga

Apr 28, 2021

10:01AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2021 Benzinga

09:30AM EDT Roth Capital Initiates Coverage On Cybin with Buy Rating, Announces Price Target of $10 Benzinga

Apr 27, 2021

10:25AM EDT Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week Benzinga

Apr 26, 2021

07:15AM EDT Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003 Business Wire

Apr 21, 2021

07:15AM EDT Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction Business Wire

Apr 19, 2021

05:50PM EDT Psyched: California Psychedelics Bill Passes Second Committee, GH Research Closes $125M Series B, Study Shows Psilocybin Could Equal SSRI Results In Depression Benzinga

09:04AM EDT Cybin to Present at the Bloom Burton & Co. Healthcare Investor Conference Business Wire

07:15AM EDT Cybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony Back Business Wire

Apr 13, 2021

07:15AM EDT Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications Business Wire

Mar 30, 2021

07:15AM EDT Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe Business Wire

Mar 26, 2021

01:49PM EDT Psyched: Compass' New Patents, Cure Extends DEA License, Andrew Yang Supports Psilocybin in NYC Benzinga

08:30AM EDT NetworkNewsAudio Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, Science Drives Surging Interest in Psychedelic Therapeutics. GlobeNewswire Inc

Mar 25, 2021

08:30AM EDT via InvestorWire Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (IBN), a multifaceted financial news and publishing company for private and public entities. GlobeNewswire Inc

Mar 22, 2021

07:20AM EDT Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine Benzinga

07:15AM EDT Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003) Business Wire

Mar 17, 2021

07:15AM EDT Cybin Progresses Two Psychedelic Investigational New Drug ("IND") Candidates and Announces Completion of Its 20th Pre-Clinical Study Business Wire

Mar 16, 2021

07:15AM EDT Cybin to Present at the Oppenheimer 31st Annual Healthcare Conference Business Wire

Mar 15, 2021

07:15AM EDT Cybin to Present at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference Business Wire

Mar 10, 2021

09:15AM EST Cybin to Present at the Stifel GMP Healthcare Conference - Healthcare Psychedelics: Addressing the Global Mental Health Crisis Business Wire

Mar 8, 2021

06:00AM EST Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021 Business Wire

Mar 3, 2021

06:00AM EST Cybin Inc. Announces Uplisting to OTCQB Venture Market Business Wire

Jan 11, 2021

12:19PM EST Emerging Markets Report: A Time to Grow GlobeNewswire Inc

Dec 22, 2020

09:13AM EST Have Psychedelics Become The Next Neuroscience Biotech Frontier? Benzinga

Share